New biosimilar - Starjemza (ustekinumab-hmny)

Indicated for 1) moderate-severe plaque psoriasis in adult and pediatric patients 6 years and older; 2) psoriatic arthritis in adult and pediatric patients 6 years and older; 3) moderate-severe Crohn disease in adult patients; and 4) moderate-severe ulcerative colitis in adult patients.